Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 17/20 | 0.61 |
| ▸ | GSK3B | P49841 | 4/20 | 0.53 |
| ▸ | AKT1 | P31749 | 5/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4920000 | 0.88 | AKT2 (0.69) | AKT2GSK3BAKT1CYP2D6CYP2C9 | |
| SCHEMBL4779830 | 0.78 | AKT2 (0.52) | AKT2GSK3BAKT1CYP2C9PBK | |
| SCHEMBL4779828 | 0.78 | AKT2 (0.52) | AKT2GSK3BAKT1CYP2C9PBK | |
| SCHEMBL4727707 | 0.76 | AKT2 (0.52) | AKT2GSK3BAKT1PBKNUDT1 | |
| SCHEMBL1000908 | 0.76 | AKT2 (1.00) | AKT2GSK3BAKT1CYP2D6CYP2C9 | |
| SCHEMBL1003117 | 0.73 | AKT2 (0.74) | AKT2GSK3BAKT1CYP2D6CYP2C9 | |
| SCHEMBL1001941 | 0.70 | AKT2 (1.00) | AKT2GSK3BAKT1CYP2D6CYP2C9 | |
| SCHEMBL29869807 | 0.69 | JAK3 (0.58) | AKT2GSK3BPBKNUDT1 | |
| SCHEMBL16105902 | 0.69 | AKT2 (0.62) | AKT2GSK3BAKT1CYP2D6CYP2C9 | |
| SCHEMBL12547303 | 0.68 | AKT2 (0.52) | AKT2GSK3BAKT1PBKNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | AKT2 1098/4885GSK3B 1722/4885AKT1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.